Tassi, Elena
Garman, Khalid A.
Schmidt, Marcel O.
Ma, Xiaoting
Kabbara, Khaled W.
Uren, Aykut
Tomita, York
Goetz, Regina
Mohammadi, Moosa
Wilcox, Christopher S.
Riegel, Anna T.
Carlstrom, Mattias
Wellstein, Anton http://orcid.org/0000-0002-0570-4950
Funding for this research was provided by:
Vetenskapsrådet (2016-01381)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA71508)
Article History
Received: 27 February 2018
Accepted: 10 October 2018
First Online: 29 October 2018
Competing Interests
: A.W. declares competing interests since he is named as inventor on a Georgetown University patent related to treatments for lowering glucose levels using FGFBP3, described in this manuscript. All other authors have declared that no conflict of interest exists.